Evidence map›Paper›PMID 32154065›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020

PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP/TAZ Pathway.

Shengjun Fan, Trevor Price, Wei Huang, Michelle Plue, Jonathan Warren, Pasupathi Sundaramoorthy, Barry Paul, Daniel Feinberg, Nancie MacIver, Nelson Chao and 2 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Shengjun FanDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.ORCID https://orcid.org/0000-0002-3096-3508
Trevor PriceDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Wei HuangDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Michelle PlueShared Materials Instrumentation Facility Pratt School of Engineering Duke University Durham NC 27708 USA.
Jonathan WarrenDepartment of Pediatrics Duke University Durham NC 27710 USA.
Pasupathi SundaramoorthyDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Barry PaulDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Daniel FeinbergDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Nancie MacIverDepartment of Pediatrics Duke University Durham NC 27710 USA.
Nelson ChaoDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Dorothy SipkinsDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Yubin KangDivision of Hematologic Malignancies and Cellular Therapy Department of Medicine Duke University Medical Center Durham NC 27710 USA.
Duke University · US

Funding

Clinical Trial of ABC294640 in Patients with Refractory Multiple MyelomaR44CA199767 · NCI · APOGEE BIOTECHNOLOGY CORPORATION · PI SMITH, CHARLES D · 2015 to 2017
$2.0M
Targeting sphingosine kinase 2 for the treatment of multiple myelomaR01CA197792 · NCI · DUKE UNIVERSITY · PI KANG, YUBIN · 2015 to 2019
$1.8M
Effects of PPAR agonists on response to immunomodulatory agents in patients with multiple myelomaR21CA234701 · NCI · DUKE UNIVERSITY · PI KANG, YUBIN · 2019 to 2020
$385k
NCI NIH HHS R01 CA197792NCI NIH HHS R21 CA234701NCI NIH HHS R44 CA199767
6 · The paper itself

Abstract

The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN-induced putative kinase 1 (PINK1)-dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels of the PINK1-dependent mitophagy markers

Indexed as

Hippo pathwaymigration and homingmitophagyMOB1Bmultiple myelomaPINK1YAP/TAZ

Identifiers

PMID32154065
PMCPMC7055555
OpenAlexW3001803802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.